Results 111 to 120 of about 11,769,643 (158)

Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants. [PDF]

Sci Adv
Berman P, Höfer J, Mehlman H, Almekias-Siegl E, Khersonsky O, Dong Y, Heinig U, Sulimani L, Hao LK, Cohen S, Peleg Y, Meir S, Rogachev I, Meiri D, Fleishman SJ, Aharoni A.   +15 more
europepmc   +1 more source

Relapse-associated worsening in apolipoprotein E ε4 carriers with relapsing multiple sclerosis. [PDF]

J Neurol Neurosurg Psychiatry
Portaccio E, Aprea MG, De Meo E, Betti M, Addazio I, Pasto' L, Ballerini C, Nacmias B, Amato MP.   +8 more
europepmc   +1 more source

Efficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis. [PDF]

J Psychopharmacol
Wallace LM, Bujor A, Sudre G, Kennedy M, Bahnareanu DE, Mittal K.   +5 more
europepmc   +1 more source

Synthesis and Biological Evaluation of 4‑Bromo-<i>N,N-</i>dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development. [PDF]

ACS Omega
Bray E, Glatfelter GC, Maitland AD, Gonzalez NR, Walther D, Yacoub J, Baumann MH, von Salm JL.   +7 more
europepmc   +1 more source

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Psychopharmacology, 2023
5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics.
Charles D. Nichols, Robin Lester Carhart-Harris, Otto Simonsson   +2 more
exaly   +4 more sources